Citizens Initiates Coverage On Minerva Neurosciences with Market Outperform Rating, Announces Price Target of $14

Benzinga Newsdesk www.benzinga.com Positive 63.4%

Neg 0% Neu 0% Pos 63.4%

Citizens analyst Jason N. Butler initiates coverage on Minerva Neurosciences (NASDAQ:NERV) with a Market Outperform rating and announces Price Target of $14.